What are the key mechanisms of CV benefit of novel diabetes drugs?
Expert Meeting on CVD & T2DM10' education - Mar. 22, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar
Video navigation menu
- What are the mechanisms underlying the CV benefits observed with GLP-1 receptor agonists? 0:40
- Based on the CV outcomes trials with GLP-1 RAs, it is not clear yet whether there is a class effect 3:38
- SGLT2 inhibitors: which mechanisms can explain the CV benefit ? 4:03
- It is important to consider the types of patients included in trials when interpreting the results 6:13
- The trial design affects what kind of data and insights can be obtained from it 8:38
- The unexpected results with novel antidiabetic drugs raise questions on the pathophysiology of T2DM that deserve further study 9:13
This video was recorded during a two-day expert meeting among cardiologists and endocrinologists/internists, focussing on the topic of 'Exploring the role of GLP-1 RA in the management of CVD & T2DM'. This video reflects the discussion in the second of 5 sessions.
Prof. Lina Badimon - cardiologist, Hospital Santa Creu and San Pau, Barcelona, Spain
Prof. Jochen Seufert - endocrinologist, Universitätsklinikum, Freiburg, Germany
Prof. Naveed Sattar -endocrinologist, University of Glasgow, United Kingdom
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for the Expert Meeting was provided by an unrestricted educational grant from Novo Nordisk. The sponsor did not attend and influence the meeting or the video recording.